Incyte Corp.
Pablo J Cagnoni (President, Global Head of R&D) sells INCY shares
AI-generated summary
Pablo J Cagnoni, President, Global Head of R&D at Incyte Corp., exercised options for 2,642 shares of common stock for a total value of $173,742. They also sold 2,642 shares of common stock for a total value of $297,780. Following these transactions, the insider directly held 183,200 shares. The sales were made under a Rule 10b5-1 trading plan.
Key facts
- Insider
- Pablo J Cagnoni · President, Global Head of R&D
Rule 10b5-1 plan
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 15, 2026 | M · exercise or conversion of a derivative | +839 | $71.93 | $60,349.27 | 184,039 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivative | +423 | $61.76 | $26,124.48 | 184,462 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivative | +455 | $61.18 | $27,836.90 | 184,917 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivative | +925 | $64.25 | $59,431.25 | 185,842 | Direct |
| Oct 15, 2026 | S · open-market saleFootnotes F1 | −2,642 | $112.71 | $297,779.82 | 183,200 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F2 | −839 | $0.00 | $0.00 | 17,627 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F3 | −423 | $0.00 | $0.00 | 3,802 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F4 | −455 | $0.00 | $0.00 | 4,096 | Direct |
| Oct 15, 2026 | M · exercise or conversion of a derivativeEmployee Stock Option (right to buy)Footnotes F5 | −925 | $0.00 | $0.00 | 19,431 | Direct |
Footnotes
- F1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
- F2 Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years.
- F3 The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
- F4 Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years.
- F5 The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
More INCY filings
- 10-Q
Filed Oct 29, 2026
- 8-K
Filed Oct 29, 2026
- 144
Filed Oct 15, 2026
- 4
Filed Oct 5, 2026
- 4
Filed Oct 2, 2026
- 4
Filed Oct 2, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.